69 results about "Docetaxel" patented technology

The invention provides a docetaxel-loaded platelet delivery system as well as a preparation method and application thereof, and relates to the technical field of medicines. According to the invention, the docetaxel-loaded platelet delivery system is obtained by loading the docetaxel with the platelets for the first time, so that the problem that in the prior art, the traditional docetaxel preparation (injection) needs to be solubilized by polysorbate 80, so that allergy is easily caused is avoided, the safety and biocompatibility of the docetaxel medicine are improved, and the docetaxel-loaded platelet delivery system is suitable for clinical application. And the docetaxel-loaded platelet delivery system has excellent stability and can be stored at normal temperature for a long time. The invention provides the preparation method of the docetaxel-loaded platelet delivery system, and the method is simple to operate, high in encapsulation efficiency and drug loading rate and suitable for popularization. The docetaxel-loaded platelet delivery system disclosed by the invention has an outstanding treatment effect on melanoma and has a good application prospect.

The present invention belongs to the field of biomedicine, and particularly relates to an lncRNA ENST00000510619 for the treatment of prostate cancer and its application. The cDNA sequence of lncRNA ENST00000510619 is shown as SEQ ID NO.1. The present invention discovers that the expression of lncRNA ENST00000510619 in mCRPC and mHSPC prostate cancer tissues is significantly higher than that in normal prostate tissues, and the expression of lncRNA ENST00000510619 in mCRPC prostate cancer tissues is significantly higher than that in mHSPC prostate cancer tissues; inhibiting / knocking out lncRNA ENST00000510619 can inhibit the proliferation, migration and invasion of prostate cancer cells, and enhance the sensitivity of docetaxel-induced apoptosis of prostate cancer cells. Therefore, lncRNA ENST00000510619 can be used as a therapeutic target for prostate cancer.

The application discloses a micelle containing a taxane drug, a preparation method and application thereof. The application provides a micelle containing substance A, which comprises the following components in parts by weight: 1 part of substance A and 5-25 parts of polyethylene glycol derivatized phospholipid; the substance A is docetaxel and / or cabazitaxel; and the polyethylene glycol derivatized phospholipid comprises a polyethylene glycol part and a phospholipid part, wherein the phospholipid part is di(C 12 ‑C 24 phosphatidylethanolamine. The micelle containing the taxane drug can contain a therapeutically effective amount of the taxane drug, the drug loading capacity is as high as 6.25%-9.09%, the stability is good, and the problems in clinical application can be effectively solved.

The invention discloses a docetaxel-based liposome drug delivery system as well as a preparation method and application thereof, and belongs to the technical field of anti-tumor nano-drugs. The delivery system is composed of an active pharmaceutical ingredient docetaxel and a specific excipient, and comprises egg yolk lecithin, phosphatidylserine, taraxasterol, protamine oligopeptide, a necessary stabilizer and a necessary pH regulator. Through an optimized preparation process, the nano drug delivery system with good stability is successfully constructed. Experiments show that the liposome is high in encapsulation efficiency and has a good application prospect.

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.

A taxane supramolecular nanocomposite. The supramolecular nanocomposite comprises a taxane active substance, including but not limited to paclitaxel, docetaxel, and cabazitaxel, as well as a self-assembling carrier, a high molecular polymer, and a dissolution promoter. The dissolution promoter may comprise one or more of alcohols, polybasic organic acids, and amino acids. Also disclosed are a preparation method and use of the supramolecular nanocomposite. The supramolecular nanocomposite is suitable for oral administration and topical application, providing effects such as increased local drug exposure concentration and efficacy, reduced systemic side effects, etc.

The present invention discloses an emulsification-aiding hydrophobic adjuvant, a synthesis method, and applications thereof. The adjuvant is composed of Fmoc-amino acids and their derivatives and fatty acid chains formed thereon. As the emulsification-aiding hydrophobic adjuvant, the Fmoc-amino acids and their derivatives are partially used to bind to hydrophobic active drugs, and the fatty acid chains are used to embed into the molecules to be emulsified. Utilizing this emulsification-aiding hydrophobic adjuvant can effectively improve the stability of albumin nanoformulations of drugs such as docetaxel, thereby facilitating the preparation of corresponding high-concentration products. Furthermore, such albumin nanoformulations do not contain hemolytic adjuvants such as polysorbate 80 and ethanol, eliminating the risk of hemolysis and enabling better drug effects.

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.

The present invention is directed to polymer-drug conjugates and / or compositions and / or nanoparticles comprising anti-cancer agents. The present invention is also directed to polymer- drug conjugates and / or compositions comprising docetaxel and the administration of docetaxel derivatives for the treatment of a number of diseases. The present invention is also directed to polymer-drug conjugates and / or compositions comprising gemcitabine or combretastatin A4 for the treatment of a number of diseases.

The invention discloses a docetaxel-loaded retinoic acid derivative polymer micelle and a preparation method thereof, and belongs to the technical field of biological medicines. The polymer micelle is prepared from docetaxel and a retinoic acid derivative polymer mPR. The preparation method comprises the following steps: mixing and dispersing the polymer mPR and docetaxel into a drug film, and hydrating with a proper medium to prepare the polymer micelle. The docetaxel polymer micelle disclosed by the invention is high in encapsulation efficiency, high in drug loading capacity, high in stability and relatively good in curative effect and safety.

The invention discloses an application of docetaxel in preparation of drugs for resisting toxoplasmosis, and belongs to the technical field of medicines. Through a series of experimental studies, it is found that docetaxel can significantly delay the onset time of mice infected with toxoplasma gondii virulent strains and effectively reduce the death rate of mice infected with toxoplasma gondii attenuated strains. Docetaxel shows a relatively strong inhibition effect in the aspect of treating related diseases caused by a virulent strain or a low virulent strain of toxoplasma gondii, and can effectively slow down the infection process and prolong the life cycle of a host. In combination with in-vitro cell experiment and in-vivo animal experiment results, the taxane drug has a good treatment prospect, can be used as a development basis of a novel toxoplasmosis-resistant drug, and promotes the realization of a novel treatment scheme.

This invention relates to the field of biomedical materials and pharmaceutical formulations, disclosing an FH peptide-polydopamine-coated graphene oxide drug delivery system and its preparation and application. The system includes an RGD peptide-modified graphene oxide carrier, a polydopamine shell, and a drug loaded within the system. The polydopamine shell is surface-modified with an FH peptide. The drugs include docetaxel and losartan, with docetaxel loaded on the RGD peptide-modified graphene oxide carrier and losartan loaded in the FH peptide-modified polydopamine shell. This FH peptide-polydopamine-coated graphene oxide drug delivery system, through surface modification of graphene oxide with an RGD peptide and coating with a polydopamine shell, effectively shields against the potential cytotoxicity and blood incompatibility risks of unmodified graphene oxide. Compared to unmodified graphene oxide carriers, this system shows significantly improved compatibility at both normal and tumor cell levels, maintaining extremely high cell viability across a wide concentration range.

The invention relates to the field of pharmaceutical preparations, and provides a TPGS modified CPD12C15 liposome as well as a preparation method and application thereof. The TPGS-modified CPD12C15 liposome is of a vesicle-shaped structure and comprises a lipid bilayer membrane which is of a closed membrane structure jointly formed by DPPC, SPC and cholesterol and forms a basic skeleton of the vesicle, and a TPGS-modified CPD12C15 liposome which is of a vesicle-shaped structure. The surface modification layer is formed by TPGS on the surface of the lipidosome, the hydrophobic end of the TPGS is inserted into the outer layer of the lipid bilayer membrane, and the hydrophilic end of the TPGS extends and is exposed on the outer surface of the lipidosome; and an internal aqueous phase, an aqueous chamber surrounded by a lipid bilayer, in which the active ingredient CPD12C15 is encapsulated; the structure of the CPD12C15 is # imgabs0 #. The liposome is prepared through a calcium acetate gradient method, the encapsulation efficiency reaches up to 79.84%, the drug loading capacity reaches 17.24%, the particle size is about 91 nm, and the PDI is lower than 0.2. The combination of the liposome and copper ions shows an excellent inhibition effect on non-small cell lung cancer cells, the IC50 value is 0.1331-0.199 [mu] mol / L and is far lower than that of docetaxel, and the multi-drug resistance of tumors can be effectively overcome.

A nanoparticle composition for rapid suspension and a preparation method therefor. The composition comprises an active ingredient, albumin and a particle stabilizer, and optionally a lyoprotectant. The active ingredient has the following characteristics: insoluble or slightly soluble in water, and soluble or easily soluble in specific organic solvents, and is preferably paclitaxel or docetaxel.

The present invention relates to a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (PCL S-PAC-PEG S) micelle in which osimertinib, etoposide, and docetaxel are encapsulated, and used thereof. Specifically, the present invention relates to a pharmaceutical composition for preventing or treating cancer, wherein osimertinib, which is a target therapeutic agent, and etoposide and docetaxel, which are both anticancer chemotherapeutic drugs, are encapsulated in a Soluplus® polymer to form micelles, whereby anticancer activity can be effectively induced through an improvement in the solubility of the poorly soluble drug in water and a synergistic action between the drugs. The pharmaceutical composition for cancer treatment according to the present invention enables effective solubilization of osimertinib, etoposide, and docetaxel by encapsulating the poorly soluble drugs in micelles formed using the PCL-PVAc-PEG (Soluplus®) polymer, and thus can be advantageously used as an intravenous injection. With the advantage of avoiding first-pass metabolism in the liver, unlike oral dosage forms, intravenous injection can reduce unnecessary loss of drugs and also increase bioavailability compared to oral dosage forms, and thus is an effective administration method capable of expecting a high effect with the same amount of drugs. Therefore, development of such a formulation allows effective administration of osimertinib, etoposide, and docetaxel. In addition, the composition of the present invention can effectively treat non-small cell lung cancer having an EGFR-sensitive mutation while preventing the development of anticancer drug resistance, which can be caused by single drug administration, by using a targeted therapeutic agent and chemotherapy in combination. Furthermore, the composition of the present invention employs a biocompatible polymer as a material of the micelle and thus has an advantage of being safe for the human body. Moreover, by combining osimertinib, etoposide, and docetaxel at a specific molar ratio and encapsulating same in Soluplus® micelles, the composition of the present invention has excellent encapsulation efficiency of three kinds of drugs and has high monodispersibility having a consistent particle size of 50-60 nm. Thus, the composition can maintain consistent product quality and has excellent formulation stability.

The present invention provides an amphiphilic acid-sensitive docetaxel polymer prodrug based on acetal bond and its preparation. The prodrug molecule provided by the present invention can be prepared by modular reaction, with simple, efficient, general and highly extensible methods. The prodrug molecule can be used to prepare docetaxel prodrug micelle preparations by self-assembly in aqueous solution. The obtained prodrug micelle preparations have the characteristics of simple preparation, good micelle stability and rapid acid-responsive activation. They are relatively stable under normal physiological pH conditions, while the acetal bond can be rapidly and responsively cleaved under acidic pH conditions, so as to realize the responsive and traceless release of docetaxel, improve the hydrophilicity of docetaxel and reduce its toxic and side effects while enhancing the anti-tumor effect.

This disclosure is directed to a pharmaceutical composition comprising sodium bicarbonate and a polymer-drug nanoaggregate having a polymer and a taxane. The polymer is water soluble and comprises at least one first terminal group modified with a hydrophobic moiety and a second terminal group modified with a hydrophilic moiety and can be a modified symmetrically or asymmetrically branched polymers. The taxane can include paclitaxel, docetaxel, cabazitaxel, larotaxel, milataxel, ortataxel, tesetaxel, derivatives therefrom or a combination thereof, which are water insoluble or poorly water soluble. Such polymer-drug nanoaggregates can improve drug solubility, stability, in vivo availability and efficacy, and reduce side effects such as renal toxicity. This invention is also directed to a process for producing the pharmaceutical composition comprising the polymer-drug nanoaggregate. This invention is further directed to a method for treating a disease including cancer using the pharmaceutical composition disclosed herein.

The invention belongs to the technical field of biology, and particularly relates to a pharmaceutical composition for inducing gonad exhaustion of paralichthys olivaceus and application of the pharmaceutical composition. The pharmaceutical composition comprises docetaxel and cis-platinum, the mass ratio of docetaxel to cis-platinum is 1: 1, and the total concentration of docetaxel and cis-platinum is 100-200 mu g / mL. By optimizing the medicine proportion and the administration scheme, the problems of low survival rate and large injury of fish bodies in the existing gonad exhaustion method are solved, and efficient and stable preparation of the paralichthys olivaceus germline stem cell transplantation receptor can be realized. By controlling the ratio of docetaxel to cis-platinum, the administration concentration, the injection frequency, the action period and the like, the invention aims to solve the problems of insufficient exhaustion effect, low fish survival rate or serious gonad injury and the like in the existing receptor preparation, and provides reliable technical support for establishing a stable and efficient paralichthys olivaceus germline stem cell transplantation receptor system.

The invention discloses a drug controlled release system based on optimal drug delivery sequence optimization and a preparation method and application thereof, and belongs to the field of pharmaceutics. The preparation method comprises the following steps: preparing a docetaxel nano preparation, and preparing poloxamer F-127 gel by adopting a cold dissolving method; metformin is dissolved in PBS to prepare a metformin solution, poloxamer F-127 gel, the metformin solution and an aqueous solution of a docetaxel nano preparation are stirred and dispersed uniformly in proportion to a homogeneous sol state, and the drug controlled release system optimized based on the optimal drug delivery sequence is obtained. According to the innovatively designed drug controlled release system MD (at) Gel, based on drug molecular weight and hydrophilic and hydrophobic differences, the metformin released firstly can block tumor cells in a mitosis G2 / M region, and the anti-tumor effect of docetaxel is remarkably improved by improving the immunosuppression microenvironment of tumors. The invention provides an innovative administration strategy and implantable instrument support for sequential chemotherapy of solid tumors.

The invention relates to a nano compound loaded with EZH2siRNA and docetaxel, which is characterized in that a zeolite imidazole skeleton (ZIF-8) is used as a carrier for siRNA delivery, then siRNA (ZIF)-8NPs is coated by using double-layer lipid, and meanwhile, the docetaxel (DTXL) is loaded in the double-layer lipid. The nano-composite loaded with EZH2siRNA and docetaxel has the beneficial effects that 1, the nano-composite loaded with EZH2siRNA and docetaxel is small in side effect as a drug, and the drug distribution at the bone metastatic focus of prostate cancer is relatively good; 2, the ZIF-8 has strong positive charges and can effectively adsorb siRNA with negative charges; 3, the nano drug loading system with a core-shell structure can more efficiently co-deliver siRNA and docetaxel, the core structure ZIF-8 can effectively load siRNA, and a shell lipid bilayer can effectively deliver a chemotherapeutic drug DTXL; and 4, the nano-composite loaded with the EZH2siRNA and the docetaxel is used as a medicine, so that the targeting property is high, and alendphosphate groups in middle and outer layer lipid DOPE-PEG-Alendronate can be effectively distributed to bone metastasis lesion in a targeting manner.

Synthesizing a docetaxel-aconitic anhydride conjugate using docetaxel, including: mixing aconitic anhydride with a chlorinating reagent to produce a first mixture; dissolving the first mixture in an organic solvent to produce a dissolved mixture; stirring the dissolved mixture; evaporating the organic solvent from the dissolved mixture to produce a second mixture; washing the second mixture with an impurity remover to remove impurities and to produce an aconitic anhydride chloride solution; and mixing the docetaxel with the produced aconitic anhydride chloride solution to produce the docetaxel-aconitic anhydride conjugate.

Disclosed herein is a method for predicting whether a subject with cancer will exhibit a beneficial response to arginine deficiency therapy. The method includes the step of determining the plasma concentration of arginine in the subject, followed by administering arginine deficiency therapy to the subject alone or in combination with an anticancer agent, based on the determined plasma concentration of arginine. According to some embodiments of this disclosure, the anticancer agent is selected from the group consisting of FOLFOX, docetaxel, cisplatin, pemetrexed, pembrolizumab, and combinations thereof.

The present invention provides a pharmaceutical composition for preventing or treating triple-negative breast cancer, comprising a mixed extract of Astragalus membranaceus, Angelica gigas, and Trichosanthes kirilowii Maximowicz; and an anticancer agent, and a method for preventing or treating cancer using the pharmaceutical composition.

The invention relates to the technical field of biological medicine, in particular to a preparation method of docetaxel-crocetin-loaded pegylated liposome as well as a product and application of the docetaxel-crocetin-loaded pegylated liposome. The preparation method comprises the following steps: firstly, carrying out esterification reaction on cholesterol and succinic anhydride under the catalysis of 4-dimethylaminopyridine to obtain succinyl cholesterol; then, butanedioyl cholesterol and methoxy polyethylene glycol are coupled through an ester bond, and pegylated cholesterol is synthesized; and finally, by taking docetaxel and crocetin as model drugs, preparing the pegylated docetaxel-crocetin liposome through a film hydration method. An in-vitro simulation drug release experiment shows that the liposome loaded with the docetaxel-crocetin can improve the slow release effect of the docetaxel and the crocetin. Dynamic light scattering and stability experiments show that the docetaxel-crocetin liposome has a small particle size and good stability. A cytotoxicity experiment shows that the liposome co-loaded with the docetaxel and the crocetin has better in-vitro anti-tumor activity and has a synergistic anti-tumor effect.

The present disclosure relates to methods of treating cancer in a subject by administering to the subject effective amounts of an anti-CCR8 antibody, a chemotherapeutic agent (e.g., cisplatin, gemcitabine, docetaxel), and a PD1 inhibitor or a PD-L1 inhibitor. In some embodiments, the chemotherapeutic agent is administered at a lower dose than in a standard of care chemotherapy regimen that does not include the anti-CCR8 antibody. In some embodiments, the chemotherapeutic agents are co-administered at a lower dose than in a standard of care chemotherapy regimen that does not include the anti-CCR8 antibody.

The invention discloses a preparation process of docetaxel albumin nanoparticles, and belongs to the technical field of biological medicine preparation, the key point of the technical scheme is that the preparation process of the docetaxel albumin nanoparticles comprises the following preparation steps: S1, dissolving docetaxel in an organic solvent; s2, controlling the pH value of the aqueous solution containing arginine in a range of 4-6; s3, adding albumin into the arginine aqueous solution obtained in the step S2, and performing low-temperature shearing to obtain an albumin arginine aqueous solution; s4, reacting the albumin arginine aqueous solution obtained in the step S3 with the mixture obtained in the step S1 to obtain a reaction solution; and S5, carrying out high-pressure homogenization on the reaction liquid to obtain the docetaxel albumin nanoparticles. The docetaxel albumin nanoparticles obtained by taking arginine as a developing solvent of albumin are completely stable within 5 hours, the stability exceeds 24 hours when the docetaxel albumin nanoparticles are stored at 4 DEG C, and the phenomenon of precipitation or precipitation does not occur.

Use of a docetaxel-albumin composition in the preparation of a drug for treating gastric cancer or gastroesophageal junction cancer, a method for treating gastric cancer or gastroesophageal junction cancer using the docetaxel-albumin composition, and a drug or kit comprising the docetaxel-albumin composition for treating gastric cancer or gastroesophageal junction cancer. The docetaxel-albumin composition can treat gastric cancer or gastroesophageal junction cancer.

The application discloses a kind of photodynamic balloon catheter systems, comprising: tube body, with opposite proximal end and distal end;Balloon, the balloon is fixed in the distal end portion of the tube body;Optical fiber assembly is inserted in the tube body, and with the light-emitting site extending to adjacent the balloon;The surface of the balloon is loaded with auxiliary material and photosensitizer in the form of coating;The photosensitizer can activate collagen and elastin under the wavelength of light 400-460nm to make them crosslink;The auxiliary material includes active drug and sustained-release material wrapped the active drug, the active drug is at least one of paclitaxel, rapamycin, zotarolimus, tacrolimus, everolimus, temsirolimus, zanolimus, biolimus, docetaxel, protein-bound paclitaxel and protein-bound dexamethasone;By the photodynamic balloon catheter system of the application can improve the utilization rate of active drug in intravascular administration.

The present disclosure relates to a method of preventing or treating brain cancers or brain metastases with mesoporous silica nanoparticles (MSNs) loaded with taxane-based chemotherapeutic drugs, in particular paclitaxel (PTX), cabazitaxel (CTX) or docetaxel (DTX), and the MSNs loaded with PTX, CTX or DTX.